Proper management of chemotoxicity in transplant patients requires detailed knowledge of
the biochemical mechanisms underlying immunosuppressant toxicity. Neurotoxicity is one of
the most significant clinical side effects of the immunosuppressive undecapeptide
cyclosporine, occurring at some degree in up to 60% of transplant patients. The clinical
symptoms of cyclosporine-mediated neurotoxicity consist of decreased responsiveness,
hallucinations, delusions, seizures, cortical blindness, and stroke-like episodes that mimic …